JP2013517299A5 - - Google Patents

Download PDF

Info

Publication number
JP2013517299A5
JP2013517299A5 JP2012549208A JP2012549208A JP2013517299A5 JP 2013517299 A5 JP2013517299 A5 JP 2013517299A5 JP 2012549208 A JP2012549208 A JP 2012549208A JP 2012549208 A JP2012549208 A JP 2012549208A JP 2013517299 A5 JP2013517299 A5 JP 2013517299A5
Authority
JP
Japan
Prior art keywords
cyclodextrin
preparation according
molar ratio
neurostimulatory
steroid anesthetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012549208A
Other languages
English (en)
Japanese (ja)
Other versions
JP5930311B2 (ja
JP2013517299A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2011/000050 external-priority patent/WO2011088503A1/en
Publication of JP2013517299A publication Critical patent/JP2013517299A/ja
Publication of JP2013517299A5 publication Critical patent/JP2013517299A5/ja
Application granted granted Critical
Publication of JP5930311B2 publication Critical patent/JP5930311B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012549208A 2010-01-21 2011-01-19 麻酔薬製剤 Active JP5930311B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29724910P 2010-01-21 2010-01-21
US61/297,249 2010-01-21
US38531810P 2010-09-22 2010-09-22
US61/385,318 2010-09-22
PCT/AU2011/000050 WO2011088503A1 (en) 2010-01-21 2011-01-19 Anaesthetic formulation

Publications (3)

Publication Number Publication Date
JP2013517299A JP2013517299A (ja) 2013-05-16
JP2013517299A5 true JP2013517299A5 (cg-RX-API-DMAC7.html) 2014-03-06
JP5930311B2 JP5930311B2 (ja) 2016-06-08

Family

ID=44306295

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012549208A Active JP5930311B2 (ja) 2010-01-21 2011-01-19 麻酔薬製剤

Country Status (27)

Country Link
US (2) US8697678B2 (cg-RX-API-DMAC7.html)
EP (1) EP2525798B1 (cg-RX-API-DMAC7.html)
JP (1) JP5930311B2 (cg-RX-API-DMAC7.html)
KR (1) KR101747476B1 (cg-RX-API-DMAC7.html)
CN (1) CN102802635B (cg-RX-API-DMAC7.html)
AU (1) AU2011207103B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012017800B1 (cg-RX-API-DMAC7.html)
CA (1) CA2786762C (cg-RX-API-DMAC7.html)
CL (1) CL2012002032A1 (cg-RX-API-DMAC7.html)
CY (1) CY1119947T1 (cg-RX-API-DMAC7.html)
DK (1) DK2525798T3 (cg-RX-API-DMAC7.html)
ES (1) ES2646829T3 (cg-RX-API-DMAC7.html)
GB (2) GB2484244B (cg-RX-API-DMAC7.html)
HR (1) HRP20171699T1 (cg-RX-API-DMAC7.html)
HU (1) HUE035441T2 (cg-RX-API-DMAC7.html)
LT (1) LT2525798T (cg-RX-API-DMAC7.html)
NO (1) NO2525798T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ601255A (cg-RX-API-DMAC7.html)
PL (1) PL2525798T3 (cg-RX-API-DMAC7.html)
PT (1) PT2525798T (cg-RX-API-DMAC7.html)
RS (1) RS56576B1 (cg-RX-API-DMAC7.html)
RU (1) RU2574022C2 (cg-RX-API-DMAC7.html)
SG (1) SG181997A1 (cg-RX-API-DMAC7.html)
SI (1) SI2525798T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201700518T1 (cg-RX-API-DMAC7.html)
WO (1) WO2011088503A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201205370B (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA017290B1 (ru) 2005-11-28 2012-11-30 Домейн Раша Инвестментс Лимитед Композиции на основе ганаксолона
US10478505B2 (en) 2011-09-23 2019-11-19 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
US9492552B2 (en) * 2011-11-29 2016-11-15 Jurox Pty Ltd Injectable aqueous pharmaceutical compositions comprising a cyclodextrin, a hydrophobic drug, a co-solvent, and a preservative
BR112014018110B1 (pt) 2012-01-23 2022-06-07 Sage Therapeutics, Inc Composições farmacêutica aquosas formuladas para administração parenteral e uso de alopregnanolona e sulfobutiléter-b-ciclodextrina
US20140050789A1 (en) 2012-08-13 2014-02-20 The Regents Of The University Of California Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
IL294306B2 (en) * 2012-08-21 2024-01-01 Sage Therapeutics Inc Methods of treating epilepsy or status epilepticus
US9757391B2 (en) 2012-11-09 2017-09-12 Goodchild Investments Pty Ltd Neuroactive steroids and their use to facilitate neuroprotection
US20150313915A1 (en) 2012-11-30 2015-11-05 The Regents Of The University Of California Anticonvulsant activity of steroids
WO2015134670A1 (en) * 2014-03-05 2015-09-11 Mingbao Zhang Deuterated ganaxolone derivatives
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
EP4059522A1 (en) * 2015-02-06 2022-09-21 Marinus Pharmaceuticals, Inc. Intravenous ganaxolone formulations and their use in treating status epilepticus and other seizure disorders
MA45276A (fr) * 2015-06-18 2018-04-25 Sage Therapeutics Inc Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
US10780099B2 (en) * 2015-10-16 2020-09-22 Marinus Pharmaceuticals, Inc. Injectable neurosteroid formulations containing nanoparticles
US20200306265A1 (en) 2016-03-08 2020-10-01 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
KR20230050474A (ko) 2016-08-11 2023-04-14 오비드 테라퓨틱스 인크. 간질 장애의 치료를 위한 방법 및 조성물
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
EP3782937B1 (en) 2018-04-16 2022-08-24 Kawasaki Jukogyo Kabushiki Kaisha Belt conveyor
US11472833B2 (en) 2018-07-03 2022-10-18 Drawbridge Pharmaceuticals Pty Ltd Neuroactive steroids and methods of preparation
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
WO2020123551A1 (en) * 2018-12-10 2020-06-18 Halo Science LLC Stable formulations of anesthetics and associated dosage forms
MX2022001553A (es) 2019-08-05 2022-04-18 Marinus Pharmaceuticals Inc Ganaxolona para su uso en el tratamiento del estado epileptico.
IL293525A (en) 2019-12-06 2022-08-01 Marinus Pharmaceuticals Inc Ganaxolone for use in the treatment of multiple sclerosis complex
US11969434B1 (en) 2022-08-29 2024-04-30 Lipocine Inc. Oral allopregnanolone compositions and methods of use
US12186327B2 (en) 2022-08-29 2025-01-07 Lipocine Inc. Oral allopregnanolone compositions and methods of use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2062359T3 (es) 1989-05-24 1994-12-16 Innovet Inc Un procedimiento de preparacion de una composicion anestesica o hipnotica esteroidal hipoalergenica.
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
WO1993017711A1 (en) 1992-03-11 1993-09-16 Australian Commercial Research & Development Limited New cyclodextrins and new formulated drugs
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
JP4227675B2 (ja) * 1996-10-25 2009-02-18 康武 日地 神経毒軽減麻酔剤
AUPQ633900A0 (en) * 2000-03-20 2000-04-15 Jurox Pty Ltd Anaesthetic composition
RU2288921C2 (ru) * 2000-12-19 2006-12-10 Калифорниа Инститьют оф Текнолоджи Композиции, содержащие комплексы включения
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
AU2002254309B2 (en) * 2001-03-20 2006-02-02 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
IL152575A (en) * 2002-10-31 2008-12-29 Transpharma Medical Ltd A skin-to-skin transmission system of water-insoluble drugs
EA017290B1 (ru) * 2005-11-28 2012-11-30 Домейн Раша Инвестментс Лимитед Композиции на основе ганаксолона

Similar Documents

Publication Publication Date Title
JP2013517299A5 (cg-RX-API-DMAC7.html)
SI2525798T1 (en) Anesthetic formulation
JP2013018787A5 (cg-RX-API-DMAC7.html)
JP2019131596A5 (cg-RX-API-DMAC7.html)
JP2012526215A5 (cg-RX-API-DMAC7.html)
JP2016512425A5 (cg-RX-API-DMAC7.html)
JP2010195825A5 (cg-RX-API-DMAC7.html)
JP2011088913A5 (cg-RX-API-DMAC7.html)
JP2011251975A5 (cg-RX-API-DMAC7.html)
JP2016505044A5 (cg-RX-API-DMAC7.html)
WO2007095976A3 (de) Adjuvanz in form einer lipid-modifizierten nukleinsäure
BRPI0920460A2 (pt) eixo de torcao com espessura de parede variavel longitudinalmente
NZ603411A (en) Pazopanib compositions and their use in treating ocular diseases
JP2010535814A5 (cg-RX-API-DMAC7.html)
JP2010507451A5 (cg-RX-API-DMAC7.html)
JP2011500690A5 (cg-RX-API-DMAC7.html)
JP2011529948A5 (cg-RX-API-DMAC7.html)
JP2015534578A5 (cg-RX-API-DMAC7.html)
JP2010522208A5 (cg-RX-API-DMAC7.html)
JP2013517277A5 (cg-RX-API-DMAC7.html)
JP2013537423A5 (cg-RX-API-DMAC7.html)
JP2015531750A5 (cg-RX-API-DMAC7.html)
JP2016147858A5 (cg-RX-API-DMAC7.html)
JP2016510019A5 (cg-RX-API-DMAC7.html)
JP2013529665A5 (cg-RX-API-DMAC7.html)